The Patent Finder

PH Health Limited

40 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Jun 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 8, 2027
    The maintenance fee for Varenicline Compound and Process of Manufacture Thereof (US 11,717,524) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
  • 2 fees due Mar 1 to 12, 2027 · next Mar 1
  • 1 fee due Apr 10, 2027
    The maintenance fee for Vareniciline Compound and Process of Manufacture Thereof (US 11,779,587) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
  • 1 fee due May 7, 2027
    The maintenance fee for Isoproterenol Compositions and Methods (US 11,806,320) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 1 fee due Jul 16, 2027
    The maintenance fee for Varenicline Compound and Process of Manufacture Thereof (US 11,872,234) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
  • 1 fee due Sep 29, 2027
    The maintenance fee for Epinephrine Formulations (US 9,295,657) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
  • 1 fee due Oct 21, 2027
    The maintenance fee for Epinephrine Formulations (US 10,624,864) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,808,737Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
In force
 · High confidence
In forceHigh confidence
US 9,789,103Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
In force
 · High confidence
In forceHigh confidence
US 11,389,443Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
In force
 · High confidence
In forceHigh confidence
US 9,375,478Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,687,526Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,744,209Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,744,239Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,750,785Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,919,026Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
US 9,925,233Vasopressin Formulations for Use in Treatment of Hypotension
In force
 · Low confidence
In forceLow confidence
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited